Evaluating Axial Inflammation in Psoriatic Arthritis Patients

This chapter presents findings from a phase four analysis of apremilas aimed at reducing axial inflammation in psoriatic arthritis patients, showcased at the 2024 ACR conference. It highlights a systematic review indicating positive responses to rituximab and a study utilizing whole body MRI to assess apremilas' impact on axial disease.